HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by von Eynatten, M. Articles by Dugi, K. A. Search for Related Content PubMed PubMed Citation Articles by von Eynatten, M. Articles by Dugi, K. A. Social Bookmarking                What's this?

Decreased Plasma Lipoprotein Lipase in Hypoadiponectinemia

An association independent of systemic inflammation and insulin resistance

¹ Department of Medicine I (Endocrinolgy and Metabolism), Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany
² Department of Medicine III (Cardiology), Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany

Address correspondence and reprint requests to Maximilian von Eynatten, Department of Medicine I (Endocrinology and Metabolism), University of Heidelberg, INF 410, D-69120 Heidelberg, Germany. E-mail: maximilian.eynatten{at}med.uni-heidelberg.de

	ABSTRACT

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
OBJECTIVE—Adiponectin is a plasma protein expressed in adipose tissue. Hypoadiponectinemia is associated with low HDL cholesterol and high plasma triglycerides, which also characterize lipoprotein lipase (LPL) deficiency syndromes. Recently, dramatically increased LPL activity was reported in mice overexpressing adiponectin. We therefore speculated that adiponectin may directly affect LPL in humans.

RESEARCH DESIGN AND METHODS—We measured plasma adiponectin and postheparin LPL in 206 nondiabetic men and in a second group of 110 patients with type 2 diabetes. Parameters were correlated with markers of systemic inflammation (C-reactive protein [CRP]) and insulin resistance (homeostatis model assessment of insulin resistance [HOMA-IR]).

RESULTS—Nondiabetic subjects with decreased plasma adiponectin had lower LPL activity (r = 0.42, P < 0.0001). This association of plasma adiponectin with LPL activity was confirmed in the second group of patients with type 2 diabetes (r = 0.37, P < 0.0001). Multivariate analysis revealed that adiponectin was the strongest factor influencing LPL activity, accounting for 23% of the variation in LPL activity in nondiabetic subjects and for 26% of the variation in LPL activity in type 2 diabetic patients. These associations were independent of plasma CRP and HOMA-IR.

CONCLUSIONS—These results demonstrate an association of decreased postheparin LPL activity with low plasma adiponectin that is independent of systemic inflammation and insulin resistance. Therefore, LPL may represent a link between low adiponectin levels and dyslipidemia in both nondiabetic individuals and patients with type 2 diabetes.

Abbreviations: CRP, C-reactive protein • ELISA, enzyme-linked immunosorbent assay • HOMA, homeostatis model assessment • HOMA-IR, HOMA of insulin resistance • hs-CRP, high-sensitivity CRP • LPL, lipoprotein lipase • TNF, tumor necrosis factor

	INTRODUCTION

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
Lipoprotein lipase (LPL) is a pivotal enzyme in lipid metabolism (1). Low LPL activity may be observed in the diabetic dyslipidemia of low HDL cholesterol and high plasma triglycerides (2). Plasma LPL activity has been shown to be decreased in insulin-resistant subjects without diabetes (3), and recently, overall plasma LPL activity was inversely associated with insulin resistance in patients with type 2 diabetes (4). LPL expression is also modulated by systemic inflammation. Tumor necrosis factor (TNF)- and interleukin-6 reduce the expression of LPL at the transcriptional level and decrease LPL activity in plasma (5,6).

Adiponectin, the gene product of the apM1 (adipose most abundant gene transcript 1) gene (7), is a member of bioactive substances known as adipocytokines. Adiponectin plasma levels are negatively correlated with BMI (8), insulin resistance (9), and type 2 diabetes (9). Furthermore, adiponectin is associated with lower TNF- expression (10) and has been shown to suppress TNF-–induced activation of nuclear transcription factor-B (11), thereby demonstrating anti-inflammatory potential. Recently published data suggest that low levels of adiponectin are associated with a lipid profile of low HDL cholesterol and increased plasma triglycerides (12) that is also characteristic for the hypertriglyceridemia in LPL deficiency. LPL is mainly expressed in muscle and adipose tissue (1), the unique source of adiponectin. These findings suggest a direct or indirect relationship between LPL and adiponectin by an unknown mechanism. We therefore investigated, in two different groups of patients, whether adiponectin influences LPL plasma activity and concentration and whether this relationship was affected by systemic inflammatory activity, insulin resistance, or overt diabetes.

	RESEARCH DESIGN AND METHODS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
We investigated two different cohorts of patients. 1) A total of 206 nondiabetic men were recruited from the University Hospital Heidelberg, Department of Medicine. All individuals in this group had diagnosed or suspected coronary artery disease and underwent elective coronary angiography. The overt diagnosis of diabetes, according to the American Diabetes Association criteria (fasting plasma glucose 126 mg/dl) (13), was an exclusion criterion. 2) A total of 110 patients (82 male and 28 female subjects) with known type 2 diabetes were recruited from the Diabetes Outpatient Clinic of the University Hospital Heidelberg.

Contraindications for heparin, treatment with subcutaneous or intravenous heparin in the previous 72 h, severe kidney or liver disease, treatment with drugs known to affect LPL activity (such as fibrates) or adiponectin plasma levels (such as peroxisome proliferator–activated receptor agonists), and a fasting triglyceride level >11.4 mmol/l (1,000 mg/dl), suggesting secondary lipid disorders, were exclusion criteria in both nondiabetic and type 2 diabetic subjects. The study was approved by the Internal Ethics Committee of Heidelberg University, and each patient gave informed consent.

Analysis of lipids/lipoproteins
Total cholesterol, HDL cholesterol, and triglyceride concentrations were determined enzymatically with a Synchron LX-20 (Beckman Coulter, Munich, Germany). LDL and VLDL were separated by ultracentrifugation in a Beckman LM-8 ultracentrifuge in 100-µl volumes with a VT-51.2 rotor (Beckman Coulter). The atherogenic index was calculated by the following formula: (total cholesterol – HDL cholesterol)/HDL cholesterol.

LPL
After an overnight fast, venous blood samples were drawn into EDTA tubes before and 10 min after intravenous injection of 60 IU heparin (Braun Melsungen, Melsungen, Germany) per kilogram of body weight. The samples were immediately chilled to 4°C, centrifuged, and stored at –80°C until assayed. Postheparin LPL activity was determined with a triolein/phosphatidylcholine emulsion as described previously (14). Regular serum was used as the source for the LPL activator apolipoprotein C-II. Selective measurement of LPL was based on the inactivation of LPL by 1.0 mol/l NaCl. The samples were quantitated in duplicate, and postheparin plasma from pooled normal control subjects was used to correct for interassay variation. The intra-assay coefficient was 7.8% and the interassay coefficient 11.4%. LPL concentration in postheparin plasma was quantitated by enzyme-linked immunosorbent assay (ELISA) (Immundiagnostik, Bensheim, Germany) using monoclonal antibodies against the COOH-terminal domain of LPL for capture and quantitation.

Blood variables
In the morning after an overnight fast, venous blood was sampled for the measurement of plasma concentrations of adiponectin, glucose, insulin, and C-reactive protein (CRP). Adiponectin samples were quantitated in duplicate by ELISA (B-Bridge International, San Jose, CA), and plasma from four normal control subjects was used for interassay variation. Both the intra- and interassay coefficients of variation were <5.0%. Plasma glucose was measured by a glucose-oxidase method. Serum insulin immunoreactivity was determined from frozen serum by ELISA (CIS bio international, Gif-Sur-Yvette, France). Plasma concentrations of CRP in a highly sensitive assay (high-sensitivity CRP [hs-CRP]) were determined by ELISA (Dade Behring, Cupertino, CA).

Assessment of insulin resistance
The degree of insulin resistance was estimated by homeostatis model assessment (HOMA) according to the method described by Matthews et al. (15). In particular, an insulin resistance score (HOMA of insulin resistance [HOMA-IR]) was computed with the following formula: fasting serum glucose (mmol/l) x fasting serum insulin (µU/ml)/22.5.

Statistical analyses
Statistical analyses were performed with SPSS for Windows (version 11.0; SPSS, Chicago, IL). Spearman correlation coefficients were used to describe the association between adiponectin and other continuous variables of interest. Linear regression models were used to control for potentially confounding variables. The models, fitted for LPL activity as a dependent variable, included age, BMI, plasma triglycerides, HDL cholesterol, HOMA-IR, hs-CRP, and adiponectin plasma concentration, as well as independent variables, to demonstrate the relative contribution of each of these variables to the outcome variable. Variables that were not normally distributed, such as plasma adiponectin, triglycerides, and hs-CRP, were log transformed to better approximate normal distributions. Results are expressed as means ± SE. A P value <0.05 was considered statistically significant.

	RESULTS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
The clinical characteristics of the subjects studied are summarized in Table 1. Table 2 shows the association between adiponectin and selected variables for both nondiabetic and diabetic subjects. LPL activity and concentration were highly correlated with each other (P < 0.001) in both cohorts, as expected (16). Therefore, we mainly report the findings with LPL activity. In both nondiabetic and type 2 diabetic subjects, adiponectin levels were strongly correlated with postheparin plasma LPL activity (Fig. 1 and Table 2). As shown in Table 2, there was a significant negative correlation between plasma adiponectin levels and the concentration of plasma hs-CRP in both groups. HOMA-IR was negatively associated with plasma adiponectin in the nondiabetic group. Spearman correlation coefficients of plasma adiponectin with BMI and lipid parameters (HDL cholesterol and plasma triglycerides) were similar in the diabetic and nondiabetic subjects. We also found a significant relationship between postheparin LPL activity and HOMA-IR in both cohorts (data not shown). Patients with significant renal insufficiency have been shown to have elevated adiponectin plasma levels (17). In our patient cohort, however, very few subjects had increased plasma creatinine values. Adiponectin was not correlated with creatinine in either of our cohorts.

View larger version (17K): [in this window] [in a new window]   Figure 1— Correlation between LPL activity and plasma adiponectin levels in 206 nondiabetic subjects (A) and 110 patients with type 2 diabetes (B). Spearman correlation coefficients are shown.

	CONCLUSIONS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

Similar findings of dramatically raised LPL activity associated with increased plasma adiponectin levels have recently been shown in an animal model (18). Our data also confirm a significant negative association between the plasma adiponectin level and the concentration of hs-CRP that has been previously reported (19). Thus, a proinflammatory state with a decreased plasma concentration of adiponectin may result in reduced LPL expression.

In vitro, insulin is a strong determinant of LPL activity (1). In clinical studies, however, conflicting data about the association of plasma insulin levels with LPL activity have been published (20,21). Therefore, it has been suggested that the HOMA index, integrating plasma insulin levels with glycemia, may be the more reliable parameter (4). Our results show a negative correlation between postheparin LPL activity and HOMA-IR in both cohorts studied, which is consistent with previous reports (4). Plasma adiponectin has been shown to be inversely correlated with insulin resistance (9). This capability of adiponectin to increase insulin sensitivity may therefore point to an indirect effect of adiponectin on plasma LPL activity. Our findings, however, show that the relationship between adiponectin and postheparin LPL activity and concentration is independent of both adiponectin effects on whole-body insulin sensitivity and systemic inflammation.

Multivariate regression analyses, including HOMA-IR as a marker of insulin resistance and hs-CRP as a marker of systemic inflammation, revealed that plasma adiponectin was the strongest independent factor influencing plasma LPL activity in both groups studied and accounted for 23 and 26% of the observed variances in posthaparin LPL activity, respectively.

In a previous study, adiponectin was associated with an antiatherogenic lipid profile (12), but the mechanism by which adiponectin influences lipid metabolism has not been elucidated. We now show for the first time a significant relationship between plasma adiponectin and lipid metabolism that is independent of inflammation and insulin resistance. We speculate that adiponectin, in addition to its anti-inflammatory properties, may directly stimulate the expression of LPL. Thus, increased LPL activity stimulated by increased adiponectin levels might result in elevated plasma HDL cholesterol and antiatherogenic changes in lipid profile because a positive association between LPL activity and HDL levels is known (22).

In summary, we demonstrate for the first time that plasma levels of adiponectin are significantly correlated with LPL activity in two independent cohorts, nondiabetic individuals and patients with type 2 diabetes. This relationship is independent of systemic inflammatory activity and unaffected by the link of adiponectin with insulin resistance.

	Acknowledgments

 
This work was supported in part by a research grant from Pfizer (ATV-D-01-006G). J.G.S. has received support from the National Institutes of Health (Grant DK07296-23) since November 2002.

	Footnotes

 
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

Received for publication July 9, 2004. Accepted for publication September 8, 2004.

	References

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 

1. Santamarina-Fojo S, Dugi KA: Structure, function and role of lipoprotein lipase in lipoprotein metabolism. Curr Opin Lipidol 5:117–125, 1994[Medline]
   
2. Taskinen MR: Lipoprotein lipase in diabetes. Diabetes Metab Rev 3:551–570, 1987[Medline]
   
3. Knudsen P, Erikkson J, Lahdenperä S, Kahri J, Groop L, Taskinen MR: Changes of lipolytic enzymes cluster with insulin resistance syndrome. Diabetologia 38:344–350, 1995[Medline]
   
4. Erikkson JW, Buren J, Svensson M, Olivecrona T, Olivecrona G: Postprandial regulation of blood lipids and adipose tissue lipoprotein lipase in type 2 diabetes patients and healthy control subjects. Atherosclerosis 166:359–367, 2003[Medline]
   
5. Semb H, Peterson J, Tavernier J, Olivecrona T: Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem 262:8390–8394, 1987[Abstract/Free Full Text]
   
6. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209–214, 2000[Medline]
   
7. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 221:286–289, 1996[Medline]
   
8. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83, 1999[Medline]
   
9. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Naka-mura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599, 2000[Abstract/Free Full Text]
   
10. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G: Adiponectin expression from human adipose tissue: relation with obesity, insulin resistance, and tumor necrosis factor- expression. Diabetes 52:1779–1785, 2003[Abstract/Free Full Text]
    
11. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida H, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Adiponectin, an adipoyte-derived plasma protein, inhibits endothelial NF-B signaling through a cAMP-dependent pathway. Circulation 102:1296–1301, 2000[Abstract/Free Full Text]
    
12. Matsubara M, Maruoka S, Katayose S: Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Enodcrinol Metab 87:2764–2769, 2000
    
13. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197, 1997[Medline]
    
14. Iverius PH, Brunzell JD: Human adipose tissue lipoprotein lipase: changes with feeding and relation to postheparin plasma enzyme. Am J Physiol 249:E107–E114, 1985
    
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419, 1985[Medline]
    
16. Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T: Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol 15:1086–1093, 1995[Abstract/Free Full Text]
    
17. Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD: Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis 43:1047–1055, 2004[Medline]
    
18. Combs TP, Utpal PB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki A, Rajala MW, Parlow AF, Cheeseboro L, Ding Y, Russell RG, Lindemann D, Hartley A, Baker G, Obici S, Deshaies Y, Ludgate ME, Rossetti L, Scherer PE: A transgenic mouse with deletion in the collageneous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145:367–383, 2004[Abstract/Free Full Text]
    
19. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107:671–674, 2003[Abstract/Free Full Text]
    
20. Desmeules A, Couillard C, Tchernof A, Bergeron J, Rankinen T, Leon AS, Rao DC, Skinner JS, Wilmore JH, Despres JP, Bouchard C: Post-heparin lipolytic enzyme activities, sex hormones and sex hormone-binding globulin (SHBG) in men and women: the HERITAGE Family Study. Atherosclerosis 171:343–350, 2003[Medline]
    
21. Tan KC, Cooper MB, Ling KL, Griffin BA, Freeman DJ, Packard CJ, Shepard J, Hales CN, Betteridge DJ: Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insilin-dependent diabetic patients with and without hypertriglyceridemia: the involvement of insulin, insulin precursor species and insulin resistance. Atherosclerosis 113:273–287, 1995[Medline]
    
22. Kuusi T, Ehnholm C, Viikari J, Harkonen R, Vartiainen E, Puska P, Taskinen MR: Postheparin plasma lipoprotein and hepatic lipase are determinants of hypo- and hyperalphalipoproteinemia. J Lipid Res 30:1117–1126, 1989[Abstract]
    

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				P. K.-T. Li, B. C.-H. Kwan, C. C. Szeto, and G. T.-C. Ko Metabolic syndrome in peritoneal dialysis patients NDT Plus, August 1, 2008; 1(4): 206 - 214. [Abstract] [Full Text] [PDF]

				L. Qiao, C. Zou, D. R. van der Westhuyzen, and J. Shao Adiponectin Reduces Plasma Triglyceride by Increasing VLDL Triglyceride Catabolism Diabetes, July 1, 2008; 57(7): 1824 - 1833. [Abstract] [Full Text] [PDF]

				D. P. Rose, S. M. Haffner, and J. Baillargeon Adiposity, the Metabolic Syndrome, and Breast Cancer in African-American and White American Women Endocr. Rev., December 1, 2007; 28(7): 763 - 777. [Abstract] [Full Text] [PDF]

				S. M. Nelson, N. Sattar, D. J. Freeman, J. D. Walker, and R. S. Lindsay Inflammation and Endothelial Activation Is Evident at Birth in Offspring of Mothers With Type 1 Diabetes Diabetes, November 1, 2007; 56(11): 2697 - 2704. [Abstract] [Full Text] [PDF]

				D. M. Maahs, L. G. Ogden, J. K. Snell-Bergeon, G. L. Kinney, R. P. Wadwa, J. E. Hokanson, D. Dabelea, A. Kretowski, R. H. Eckel, and M. Rewers Determinants of Serum Adiponectin in Persons with and without Type 1 Diabetes Am. J. Epidemiol., September 15, 2007; 166(6): 731 - 740. [Abstract] [Full Text] [PDF]

				B. C.H. Kwan, M. A. Murtaugh, and S. Beddhu Associations of Body Size with Metabolic Syndrome and Mortality in Moderate Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 992 - 998. [Abstract] [Full Text] [PDF]

				N. Matikainen, S. Manttari, J. Westerbacka, S. Vehkavaara, N. Lundbom, H. Yki-Jarvinen, and M.-R. Taskinen Postprandial Lipemia Associates with Liver Fat Content J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3052 - 3059. [Abstract] [Full Text] [PDF]

				K. J. Mukamal, R. H. Mackey, L. H. Kuller, R. P. Tracy, R. A. Kronmal, M. A. Mittleman, and D. S. Siscovick Alcohol Consumption and Lipoprotein Subclasses in Older Adults J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2559 - 2566. [Abstract] [Full Text] [PDF]

				M. E. Trujillo and P. E. Scherer Adipose Tissue-Derived Factors: Impact on Health and Disease Endocr. Rev., December 1, 2006; 27(7): 762 - 778. [Abstract] [Full Text] [PDF]

				A. M. Kanaya, C. Wassel Fyr, E. Vittinghoff, P. J. Havel, M. Cesari, B. Nicklas, T. Harris, A. B. Newman, S. Satterfield, S. R. Cummings, et al. Serum Adiponectin and Coronary Heart Disease Risk in Older Black and White Americans J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 5044 - 5050. [Abstract] [Full Text] [PDF]

				Y. W. Asmann, C. S. Stump, K. R. Short, J. M. Coenen-Schimke, Z. Guo, M. L. Bigelow, and K. S. Nair Skeletal Muscle Mitochondrial Functions, Mitochondrial DNA Copy Numbers, and Gene Transcript Profiles in Type 2 Diabetic and Nondiabetic Subjects at Equal Levels of Low or High Insulin and Euglycemia Diabetes, December 1, 2006; 55(12): 3309 - 3319. [Abstract] [Full Text] [PDF]

				J. C. Winer, T. L. Zern, S. E. Taksali, J. Dziura, A. M. G. Cali, M. Wollschlager, A. A. Seyal, R. Weiss, T. S. Burgert, and S. Caprio Adiponectin in Childhood and Adolescent Obesity and Its Association with Inflammatory Markers and Components of the Metabolic Syndrome J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4415 - 4423. [Abstract] [Full Text] [PDF]

				W. Koenig, N. Khuseyinova, J. Baumert, C. Meisinger, and H. Lowel Serum Concentrations of Adiponectin and Risk of Type 2 Diabetes Mellitus and Coronary Heart Disease in Apparently Healthy Middle-Aged Men: Results From the 18-Year Follow-Up of a Large Cohort From Southern Germany J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1369 - 1377. [Abstract] [Full Text] [PDF]

				K. Kantartzis, K. Rittig, B. Balletshofer, J. Machann, F. Schick, K. Porubska, A. Fritsche, H.-U. Haring, and N. Stefan The Relationships of Plasma Adiponectin with a Favorable Lipid Profile, Decreased Inflammation, and Less Ectopic Fat Accumulation Depend on Adiposity Clin. Chem., October 1, 2006; 52(10): 1934 - 1942. [Abstract] [Full Text] [PDF]

				T. Pischon and E. B. Rimm Adiponectin: a promising marker for cardiovascular disease. Clin. Chem., May 1, 2006; 52(5): 797 - 799. [Full Text] [PDF]

				B. Buemann, A. Astrup, O. Pedersen, E. Black, C. Holst, S. Toubro, S. Echwald, J. J. Holst, C. Rasmussen, and T. I. A. Sorensen Possible Role of Adiponectin and Insulin Sensitivity in Mediating the Favorable Effects of Lower Body Fat Mass on Blood Lipids J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1698 - 1704. [Abstract] [Full Text] [PDF]

				M. von Eynatten, A. Hamann, D. Twardella, P. P. Nawroth, H. Brenner, and D. Rothenbacher Relationship of Adiponectin with Markers of Systemic Inflammation, Atherogenic Dyslipidemia, and Heart Failure in Patients with Coronary Heart Disease Clin. Chem., May 1, 2006; 52(5): 853 - 859. [Abstract] [Full Text] [PDF]

				J. G. Schneider, M. von Eynatten, S. Schiekofer, P. P. Nawroth, and K. A. Dugi Low Plasma Adiponectin Levels Are Associated With Increased Hepatic Lipase Activity In Vivo: Response to Kobayashi et al. Diabetes Care, January 1, 2006; 29(1): 181 - 181. [Full Text] [PDF]

				J. Kobayashi, Y. Murase, M.-a. Kawashiri, A. Nohara, A. Inazu, and H. Mabuchi Low Plasma Adiponectin Levels Are Associated With Increased Hepatic Lipase Activity In Vivo: Response to Schneider et al. Diabetes Care, January 1, 2006; 29(1): 181 - 182. [Full Text] [PDF]

				G. M. van der Vleuten, L. J. H. van Tits, M. den Heijer, H. Lemmers, A. F. H. Stalenhoef, and J. de Graaf Decreased adiponectin levels in familial combined hyperlipidemia patients contribute to the atherogenic lipid profile J. Lipid Res., November 1, 2005; 46(11): 2398 - 2404. [Abstract] [Full Text] [PDF]

				J. G. Schneider, M. von Eynatten, S. Schiekofer, P. P. Nawroth, and K. A. Dugi Low Plasma Adiponectin Levels Are Associated With Increased Hepatic Lipase Activity In Vivo Diabetes Care, September 1, 2005; 28(9): 2181 - 2186. [Abstract] [Full Text] [PDF]

				S. Pilz, R. Horejsi, R. Moller, G. Almer, H. Scharnagl, T. Stojakovic, R. Dimitrova, G. Weihrauch, M. Borkenstein, W. Maerz, et al. Early Atherosclerosis in Obese Juveniles Is Associated with Low Serum Levels of Adiponectin J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4792 - 4796. [Abstract] [Full Text] [PDF]

				Y.-H. Yu and H. N. Ginsberg Adipocyte Signaling and Lipid Homeostasis: Sequelae of Insulin-Resistant Adipose Tissue Circ. Res., May 27, 2005; 96(10): 1042 - 1052. [Abstract] [Full Text] [PDF]

				M.-P. Chen, J. C.-R. Tsai, F.-M. Chung, S.-S. Yang, L.-L. Hsing, S.-J. Shin, and Y.-J. Lee Hypoadiponectinemia Is Associated With Ischemic Cerebrovascular Disease Arterioscler. Thromb. Vasc. Biol., April 1, 2005; 25(4): 821 - 826. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by von Eynatten, M. Articles by Dugi, K. A. Search for Related Content PubMed PubMed Citation Articles by von Eynatten, M. Articles by Dugi, K. A. Social Bookmarking                What's this?